RedHill Biopharma Ltd. (RDHL)Healthcare | Drug Manufacturers - Specialty & Generic | Tel Aviv-Yafo, Israel | NasdaqCM
0.69 USD
-0.01
(-1.939%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 0.69 0.00 (-0.003%) ⇩ (July 13, 2026, 4:29 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:11 a.m. EDT
The immediate outlook is severely clouded by a relentless downward price trend and deteriorating financial health. Over the last nine years, the stock has lost nearly 99.98% of its value, with the five most recent annual periods showing consecutive declines, signaling a deep structural failure rather than a temporary setback. Fundamentally, the company is bleeding cash, reporting negative operating margins of roughly 27%, negative free cash flow, and a precarious current ratio of 0.34, indicating liquidity stress. While recent headlines mention regulatory compliance and potential GLP-1 progress, these are insufficient to counteract the massive capital destruction evident in the price history and the lack of any dividend support. The statistical forecast offers almost no directional guidance, reinforcing the view that the current trajectory is a continuation of a long-term decline. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.102982 |
| AutoETS | 0.103061 |
| AutoARIMA | 0.103061 |
| MSTL | 0.123884 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 19.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.121 |
| Excess Kurtosis | -1.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 25.07 |
| Revenue per Share | 0.091 |
| Market Cap | 4,214,077 |
| Trailing P/E | Infinity |
| Forward P/E | 23.10 |
| Beta | 4.97 |
| Profit Margins | -150.00% |
| Website | https://www.redhillbio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.68119264 |
| Address1 | 21 Ha’arba’a Street |
| All Time High | 22,220.0 |
| All Time Low | 0.685 |
| Ask | 0.8749 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 63,530 |
| Average Daily Volume3 Month | 216,240 |
| Average Volume | 216,240 |
| Average Volume10Days | 63,530 |
| Beta | 4.97 |
| Bid | 0.49 |
| Bid Size | 2 |
| Book Value | 0.838 |
| City | Tel Aviv-Yafo |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.693 |
| Current Ratio | 0.34 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.722 |
| Day Low | 0.637 |
| Debt To Equity | 25.07 |
| Display Name | RedHill Biopharma |
| Earnings Timestamp End | 1,744,282,805 |
| Earnings Timestamp Start | 1,744,282,805 |
| Ebitda | -7,793,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.081 |
| Enterprise To Revenue | 2.196 |
| Enterprise Value | 627,981 |
| Eps Forward | 0.03 |
| Eps Trailing Twelve Months | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 3 541 3144 |
| Fifty Day Average | 0.92412 |
| Fifty Day Average Change | -0.23111999 |
| Fifty Day Average Change Percent | -0.25009736 |
| Fifty Two Week Change Percent | -68.11926 |
| Fifty Two Week High | 3.31 |
| Fifty Two Week High Change | -2.6169999 |
| Fifty Two Week High Change Percent | -0.7906344 |
| Fifty Two Week Low | 0.637 |
| Fifty Two Week Low Change | 0.055999994 |
| Fifty Two Week Low Change Percent | 0.087912075 |
| Fifty Two Week Range | 0.637 - 3.31 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,357,569,000,000 |
| Float Shares | 4,203,460 |
| Forward Eps | 0.03 |
| Forward P E | 23.1 |
| Free Cashflow | -2,176,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 286,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.03542 |
| Implied Shares Outstanding | 6,080,920 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,112,000 |
| Last Split Factor | 1:25 |
| Long Business Summary | RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel. |
| Long Name | RedHill Biopharma Ltd. |
| Market | us_market |
| Market Cap | 4,214,077 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_104926324 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -8,080,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,226,239 |
| Open | 0.71 |
| Operating Cashflow | -7,191,000 |
| Operating Margins | -27.65385 |
| Payout Ratio | 0.0 |
| Phone | 972 3 541 3131 |
| Post Market Change | -0.003000021 |
| Post Market Change Percent | -0.43290344 |
| Post Market Price | 0.69 |
| Post Market Time | 1,783,974,570 |
| Previous Close | 0.7067 |
| Price Hint | 4 |
| Price To Book | 0.82696897 |
| Price To Sales Trailing12 Months | 14.734535 |
| Profit Margins | -1.5 |
| Quick Ratio | 0.295 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0137 |
| Regular Market Change Percent | -1.93859 |
| Regular Market Day High | 0.722 |
| Regular Market Day Low | 0.637 |
| Regular Market Day Range | 0.637 - 0.722 |
| Regular Market Open | 0.71 |
| Regular Market Previous Close | 0.7067 |
| Regular Market Price | 0.693 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 153,822 |
| Return On Assets | -0.22785999 |
| Revenue Per Share | 0.091 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 6,080,920 |
| Shares Percent Shares Out | 0.0050999997 |
| Shares Short | 31,149 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 22,308 |
| Short Name | Redhill Biopharma Ltd. |
| Short Percent Of Float | 0.0052 |
| Short Ratio | 0.07 |
| Source Interval | 15 |
| Symbol | RDHL |
| Total Cash | 3,971,000 |
| Total Cash Per Share | 0.78 |
| Total Debt | 1,070,000 |
| Total Revenue | 286,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.0 |
| Trailing P E | Infinity |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.120465 |
| Two Hundred Day Average Change | -0.42746502 |
| Two Hundred Day Average Change Percent | -0.3815068 |
| Type Disp | Equity |
| Volume | 153,822 |
| Website | https://www.redhillbio.com |
| Zip | 6,473,921 |